Breast Neoplasm Malignant Primary Clinical Trial
Official title:
The Journey of Women With Breast Cancer in Mozambique: What is the Best Path? A Prospective Cohort With Patient Navigation as an Intervention to Reduce Treatment Disparities
The objective of this observational study is to introduce a patient navigation system within the breast cancer unit at Hospital Central de Maputo (MOZ) and gather data to assess the efficacy of patient navigation in enhancing oncological outcomes among this patient cohort. The primary inquiries it seeks to address are as follows: - Can patient navigation reduce the duration (in days) between patient admission and the commencement of treatment? - Does patient navigation influence overall survival rates when juxtaposed with historical cohorts from the local setting? Participants will receive continuous support from a patient navigator starting from admission until the initiation of any oncological treatment.
-General Objective: To implement an oncological navigation platform for breast cancer patients receiving treatment at Maputo Central Hospital (HCM) over a proposed period of 12 months after project approval by the local IRB. -Specific Objectives: - Develop an oncological patient navigation system for breast cancer patients treated at HCM. - Establish a prospective cohort of navigated breast cancer patients (with invasive or ductal carcinoma in situ) treated at HCM in 2024-25. - Collect diverse epidemiological data from navigated patients during the proposed study period. - Compare the time interval (in days) between admission to HCM and initiation of cancer treatment (surgery or systemic treatment) among patients in this cohort versus patients already treated in the service with available data in the National Cancer Registry (NCR). - Compare overall survival between patients in this cohort and a locally published historical cohort from 2020. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02949310 -
Effectiveness of Nefopam in Breast Cancer Surgery
|
N/A | |
Recruiting |
NCT06310330 -
TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
|
N/A | |
Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 |